1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 11,700 | 14,800 | 12.09. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Jefferies initiates Adlai Nortye stock with buy rating on drug potential | 3 | Investing.com | ||
| Do | Adlai Nortye: Jefferies sieht dank Medikamentenkandidat massives Kurspotenzial | 1 | Investing.com Deutsch | ||
| Di | Adlai Nortye Group Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| ADLAI NORTYE GROUP Aktie jetzt für 0€ handeln | |||||
| Di | Lucid Capital Markets initiates Adlai Nortye stock with buy rating | 2 | Investing.com | ||
| Di | Lucid Capital Markets startet Coverage für Adlai Nortye mit Kaufempfehlung und massivem Kurspotenzial | 2 | Investing.com Deutsch | ||
| Di | Adlai Nortye: Erster Patient in klinischer Studie mit Krebsmedikament AN4035 behandelt | 1 | Investing.com Deutsch | ||
| 26.08. | Adlai Nortye Group Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 14.08. | Adlai Nortye Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 14.08. | Adlai Nortye GAAP EPS of -$0.04, revenue of $13.06M | 2 | Seeking Alpha | ||
| 14.08. | Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress | 635 | GlobeNewswire (Europe) | Enrollment ongoing in both QD and QW arms of global Phase I trial of pan-RAS(ON) inhibitor AN9025 First regulatory approval obtained for Phase I trial of pan-RAS(ON) ADC AN4035 Two leading medical... ► Artikel lesen | |
| 03.08. | Adlai Nortye Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 03.08. | Adlai Nortye receives approval to begin trial in Australia | 3 | Investing.com | ||
| 03.08. | Adlai Nortye erhält Zulassung für klinische Studie in Australien | 3 | Investing.com Deutsch | ||
| 03.08. | Adlai Nortye Ltd.: Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia | 339 | GlobeNewswire (Europe) | First-in-class pan-RAS(ON) ADC is cleared for clinical development Designed to selectively deliver pan-RAS(ON) inhibition to tumors while minimizing systemic toxicity. IND submissions to U.S. FDA... ► Artikel lesen | |
| 17.07. | Adlai Nortye Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 16.07. | Adlai Nortye doses first patient in weekly trial arm of AN9025 | 1 | Investing.com | ||
| 16.07. | Adlai Nortye startet wöchentliche Dosierungsstudie für Krebswirkstoff AN9025 | 1 | Investing.com Deutsch | ||
| 16.07. | Adlai Nortye Ltd.: Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025 | 276 | GlobeNewswire (Europe) | First patient dosed in intermittent QW dosing arm with AN9025 Intermittent dosing offers a differentiated approach in the pan-RAS(ON) inhibitor space and may widen the therapeutic window based on... ► Artikel lesen | |
| 13.07. | Adlai Nortye expands scientific advisory board with two oncologists | 3 | Investing.com | ||
| 13.07. | Adlai Nortye Ltd.: Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists | 446 | GlobeNewswire (Europe) | SINGAPORE and NORTH BRUNSWICK, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) ("Adlai Nortye" or the "Company"), a clinical-stage biotechnology company focused on the development... ► Artikel lesen |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CLINUVEL | 4,982 | -0,64 % | Clinuvel Pharmaceuticals Ltd - 6-K, Report of foreign issuer | ||
| BIOCRYST PHARMACEUTICALS | 7,006 | 0,00 % | TD Cowen startet Coverage für BioCryst mit Kaufempfehlung dank HAE-Medikament | ||
| CARDIOL THERAPEUTICS | 1,796 | +4,42 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission | TORONTO, Sept. 10, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 4,410 | -0,23 % | Arbutus Biopharma Corporation: Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified "Dutch Auction" Tender Offer | WARMINSTER, Pa., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease... ► Artikel lesen | |
| ATAIBECKLEY | 6,250 | -0,79 % | Emyria vor Meilenstein: Erste Sydney-Klinik ist startbereit für Psychdelika-Patienten | ||
| CARDIFF ONCOLOGY | 1,040 | 0,00 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update | Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated... ► Artikel lesen | |
| ALDEYRA | 1,160 | 0,00 % | Aldeyra Therapeutics, Inc. - 10-Q, Quarterly Report | ||
| DENALI THERAPEUTICS | 18,440 | +1,51 % | Mehr als 98% bleiben draußen: Warum Roche, Denali und NurExone neue Wege ins Nervensystem suchen | ||
| ABCELLERA BIOLOGICS | 8,910 | -5,31 % | AbCellera-Aktie mit +18% - neues Allzeithoch möglich? | Die AbCellera-Aktie hat zuletzt erneut einen kräftigen Kurssprung hingelegt. Am gestrigen Handelstag ging es um +17,81% nach oben. Damit setzt sich die außergewöhnliche Rallye fort: Seit dem lokalen... ► Artikel lesen | |
| ADAPTIVE BIOTECHNOLOGIES | 20,770 | -0,48 % | CSE Bulletin: Consolidation - Adaptogenics Health Corp. (ADPT) | Le 13 juillet/July 2026
Adaptogenics Health Corp. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated share for four (4) pre-consolidated... ► Artikel lesen | |
| AC IMMUNE | 2,395 | +0,84 % | AC Immune SA: AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 | AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 ACI-19764 is an orally available inhibitor of the NLRP3 inflammasome Preliminary data showed ACI-19764 was safe... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,157 | +0,43 % | Coherus Oncology, Inc.: Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights | - Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets - - Completes transformation of Coherus Oncology into a fully integrated, innovative immuno-oncology company... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 2,856 | +0,49 % | CytomX auf Wells-Fargo-Konferenz: Fokus auf EpCAM-Wirkstoff und solide Liquidität | ||
| CYBIN | 11,320 | +1,07 % | CYBIN INC. - 6-K, Report of foreign issuer | ||
| AGENUS | 5,900 | -1,67 % | Agenus Inc.: Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026 | Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that three abstracts from investigator-sponsored trials evaluating botensilimab and balstilimab (BOT+BAL) have... ► Artikel lesen |
ADLAI NORTYE GROUP LTD ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +2,46 % bei einem Aktienkurs von 12,500 Euro. Die Dividendendrendite beträgt aktuell 0,00 % (berechnet anhand der Ausschüttung von 0,00 Euro in den letzten 12 Monaten).
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ADLAI NORTYE GROUP LTD ADR finden Sie auf Wallstreet Online.